Compare TransMedics Group Inc (TMDX) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? TransMedics Group Inc trades at $89.15 (market cap $3.07B), while Vanguard Total International Stock Index Fund ETF trades at $87.06. The key difference: Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | VXUS | |
|---|---|---|
Market Cap | $3.07B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $150.42 | $87.21 |
52-Week Low | $61.99 | $70.87 |
Enterprise Value | $3.46B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TMDX trades at $83.89, up 4.59% today, with a bullish technical signal from moving averages and strong support at $81. The company reported a Q2 2026 earnings miss ($0.44 actual vs. $0.50 expected) but beat revenue expectations, with 2025 net income at $190.29M. Analyst consensus is a Buy with a $99.57 price target, though recent news highlights a legal investigation into fiduciary duties.
Outlook remains positive due to raised revenue guidance and institutional interest, but risks include earnings volatility, margin pressure, and legal scrutiny. The stock's valuation multiples suggest growth expectations, yet execution on cost control and international expansion will be critical for sustained upside.
VXUS trades at $87.21, up 1.03% with strong bullish technical signals from moving averages. The ETF offers broad international diversification with over 8,700 non-U.S. stocks, recently delivering 27.82% total returns over the past year according to Seeking Alpha (August 8, 2026). Institutional interest is growing with multiple firms increasing positions, while analysts highlight its valuation discount to U.S. equities.
The outlook remains positive given international diversification benefits and institutional accumulation, though RSI levels suggest potential near-term consolidation. Key risks include global economic volatility and currency fluctuations. Wall Street sentiment leans bullish with Seeking Alpha maintaining a Buy rating, supported by the ETF's low expense ratio and comprehensive market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
